VEGFA and retinopathy of prematurity: To identify subgroups of infants in which the choice between treatment initiation with either laser or anti-VEGF is a valid choice, we describe clinical pathways for ROP screening and treatment among infants born at 22–23 weeks’ gestation in Sweden and map cost distributions associated with ROP screening and treatment.